Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Impulsividad basada en el afecto en el trastorno límite de la personalidad

28 de septiembre de 2026 actualizado por: University of North Carolina, Chapel Hill

Impulsividad basada en el efecto en el trastorno límite de la personalidad: desarrollar un fenotipo neurocomputacional

The purpose of this research study is to investigate how personality traits and neuroendocrine systems relate to decision-making patterns in individuals 18-45 years old. The main question it aims to answer is how neuroendocrine activity impacts decision-making.

Participants will complete online behavioral tasks, a stress induction procedure, self-report surveys, and a cognitive assessment. During the session, psychophysiological measures will be collected, including electrocardiogram (ECG) and cardiac impedance (ICG) to monitor heart rate and blood flow, as well as electrodermal activity (EDA), blood drop samples, and saliva collection to assess nervous system activity.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

76

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27514
        • University of North Carolina at Chapel Hill

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 45 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Borderline Personality Disorder (BPD) group:

  • Score of 38 or higher on Personality Assessment Inventory-Borderline Scale (PAI-BOR)
  • Participants in the BPD group will be primarily recruited from the two

DEPENd lab studies that maintain large samples of BPD participants. To ensure maximal similarity between BPD participants recruited from other DEPENd lab studies and BPD participants recruited through other recruitment sources, the investigators will use the same criteria for the BPD group in the current study as the criteria used in the other DEPENd lab studies. BPD participants in the two DEPENd lab studies from which the investigators will be recruiting must meet the following criteria:

  1. 3+ BPD symptoms, one of which must be affective instability, per clinical interview
  2. Participants must score at least 80 on the Reynolds Intellectual Screening Test (RIST).

Health Control (HC) Group:

  • Score of 12 or lower on PAI-BOR
  • Score below 50th percentile on World Health Organization Disability Assessment Schedule (WHODAS)
  • Absence of any current or lifetime psychiatric disorder, including personality disorders as determined by diagnostic interviews (SIDP and SCID), if the participant had participated in the lab's other studies (IRB Nos. 20-1735 and 21-0602).

Combined Inclusion Criteria:

  • Ages 18-45
  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  • Willingness to participate in all components of the study
  • Participants must be able to speak, understand and read English.
  • Participants must have at least 20/40 visual acuity (correct or uncorrected).

Exclusion Criteria:

  • Use of as needed antihypertensive agents within 12 hours prior to lab visit
  • Inability to refrain from using as needed psychotropic medications for 12 hours prior to lab visit
  • History of psychotic disorder, Bipolar I disorder, autism spectrum disorder, reactive attachment disorder, pervasive developmental disorder, motor disorder, head injury, mental retardation, neurological disorder, or current substance dependence
  • Family history of Bipolar I disorder in a first degree relative.
  • Participants are also excluded for any of the following: cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Stress

Participants will undergo a controlled stress induction approximately 1 hour and 35 minutes into Session 1.

Participants will complete the Trier Social Stress Test to induce stress, which includes a public speaking simulation and mental arithmetic.

Otros nombres:
  • Prueba de estrés social de Trier (TSST)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Goal-directed decision-making in the Social Decision Tree Task (SDTT)
Periodo de tiempo: Collected for 40 minutes ~2 hours into one-time study visit

Measured by choice behavior in SDTT, which is based on the decision tree framework. After each action, participants receive feedback about the effect of that action and the extent to which it added to or took away from their points. If participants make a given choice, the subsequent actions that they can choose are different than if they were to initially make a different choice.

An action in SDTT is goal-directed if the possible net gain an individual can earn before the end of the current epoch (a "day" in the SDTT) is equal to or higher than the amount they could gain by choosing the alternative action. The investigators will subset trials so that 1 is coded as choosing the immediately valuable action at the expense of the optimal and 0 is coded as choosing the optimal at the expense of the immediately valuable action. This outcome variable is binary.

Collected for 40 minutes ~2 hours into one-time study visit

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Bias toward social actions in the Social Decision Tree Task (SDTT)
Periodo de tiempo: Collected for 40 minutes ~2 hours into one-time study visit

Measured by choice behavior in SDTT, which is based on the decision tree framework. An action in SDTT is defined as social if it is paired with a visual cue with a face on it and non-social if not. This outcome variable is binary.

Collected for 40 minutes ~2 hours into one-time study visit

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in salivary cortisol
Periodo de tiempo: Collected shortly after the participant consents into the study (~20 minutes into the one-time study visit) and 20 minutes after stress induction concludes (~2 hours into one-time study visit)

The investigators will collect a saliva sample to measure baseline salivary cortisol at the beginning of the session. They will collect a second saliva sample 10 minutes after the stress induction concludes. They will measure cortisol levels in both samples through an assay. The investigators will calculate the change in salivary cortisol by subtracting the measured cortisol in the first saliva sample (collected at baseline) from the measured cortisol in the second saliva sample (collected 10 minutes after the stress induction). Salivary cortisol is measured as nmol/L. Salivary cortisol expected to generally be below 200 nmol/L.

Collected shortly after the participant consents into the study (~20 minutes into the one-time study visit) and 20 minutes after stress induction concludes (~2 hours into one-time study visit)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Keely Muscatell, PhD, University of North Carolina, Chapel Hill

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

21 de septiembre de 2025

Finalización primaria (Actual)

13 de agosto de 2026

Finalización del estudio (Actual)

13 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

11 de marzo de 2025

Primero enviado que cumplió con los criterios de control de calidad

11 de marzo de 2025

Publicado por primera vez (Actual)

18 de marzo de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de septiembre de 2026

Última verificación

1 de septiembre de 2025

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 24-3120
  • CTSC0406 (Otro número de subvención/financiamiento: The North Carolina Translational and Clinical Sciences (TraCS) Institute)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina at Chapel Hill (UNC).

Marco de tiempo para compartir IPD

Beginning 9 and continuing for 36 months following publication

Criterios de acceso compartido de IPD

Investigator who proposes to use the data has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .